INTRODUCTION
Cyclooxygenases (COX) catalyze the rate-limiting step in the biosynthesis of prostaglandins (PG) and thromboxanes from arachidonic acid. As the result of sequential reactions implicating first the cyclooxygenase and then the endoperoxidase activities of COX, arachidonic acid is converted to PGH2, which is subsequently acted upon by specific synthases to generate the biologically active prostanoids 1, 2 . Notwithstanding their largely overlapping features in structure, substrate usage and catalytic activities, the two known COX, COX-1 and COX-2, display dramatic differences both in their expression profiles and in the panel of cellular responses evoked. COX-1 is constitutively and ubiquitously expressed, while COX-2 is inducibly expressed in response to proinflammatory stimuli in monocytes, macrophages and polymorphonuclear cells. Furthermore, COX-2 is ectopically expressed in some forms of neoplasia, including colon, breast and prostate cancer 3 .
Prolonged usage of nonselective nonsteroidal anti-inflammatory drugs (NSAID), which inhibit COX activity by reversible or irreversible binding to the active site, results in gastric ulceration and bleeding, supporting a gastroprotective and homeostatic function of COX-1. On the other hand, a key role for COX-2 in inflammation has been established 4 .
This clear-cut distiction between "good" and "bad" COX has been more recently challenged both with the generation of mice deficient for either COX-1 or COX-2, and with the development of NSAID selective for each COX isozyme. The data suggest a complex interplay of COX-1 and COX-2 in the control of a number of physiological and pathophysiological functions, including inflammation and carcinogenesis [5] [6] [7] . The pleiotropic and in many cases opposite activities of COX are likely to be dictated by a number of factors, including intracellular localization and coupling to specific For personal use only. by on . www.bloodjournal.org From prostaglandin synthases, as well as by the specific cellular pattern of expression of prostanoid receptors, which are known to trigger different intracellular signaling pathways 8 .
Both COX isozymes are expressed in T lymphocytes and appear to play a role in T cell development, activation, chemotaxis, polarization and apoptosis [9] [10] [11] . In the thymus COX-1 is expressed in developing (CD4 -CD8 -and CD4 + CD8 + ) thymocytes, while COX-2 is expressed in a subset of medullary stromal cells 12 . The role of COX isozymes in T cell development has been elegantly addressed in COX deficient mice, as well as using selective COX-1 and COX-2 inhibitors in fetal thymic organ cultures. Mice deficient for COX-1 show an early block in thymic development, resulting in a dramatic reduction in double positive thymocytes, while COX-2 deficiency selectively affects maturation of single positive CD4 + thymocytes 12 . Phenocopies of COX deficiency can be obtained by pharmacological inhibition of specific COX isozymes in the fetal thymus 12 , supporting a crucial physiological role of COX in T cell development.
Although COX expression has also been documented in mature peripheral T cells, the role of these enzymes has as yet not been fully elucidated, partly because NSAID, which have been extensively used as tools to study the function of COX, display COX-independent activities related to their capacity to act as agonists of the peroxisome proliferatoractivated (PPAR) family of transcription factors 13 . As opposed to COX-1, which is constitutively expressed in T cells, COX-2 is inducibly expressed as an early response gene following TCR engagement, suggesting a role for COX-2 in T cell activation 14 . This possibility is supported by the inhibitory activity of COX-2 selective NSAID on T cell
For personal use only. by on . www.bloodjournal.org From activation and cytokine production, which correlates with the inhibition of key transcription factors 14 . We have recently shown that also COX-1 participates in the process of T cell activation. Specifically, COX-1 is required for TCR-dependent activation of p38 stress kinase, a member of the MAP kinase family activated in response to TCR engagement and required for T cell activation and differentiation 15 . Furthermore, COX-1 inhibition results in impaired COX-2 expression 15 , suggesting a sequential role of COX-1 and COX-2 in T cell activation. Here we address the impact of COX-1 inhibition on the activation of the individual molecular components of the pathway triggered by the TCR and leading to stress kinase activation. The data identify COX-1 as an early component of the tyrosine phosphorylation cascade initiated by the TCR and highlight a TCR-proximal pathway controlled by Fyn selectively coupled to stress kinase activation. To assay NF-AT activation, reporter Jurkat cells were activated by CD3 cross-linking on a secondary antibody-coated plate using OKT3 mAb as described 15 . NSAID or carrier was added 10 min prior to activation. Cells were collected 6 h after activation and processed for luciferase assays as described previously 15 . All samples were in duplicate, and each experiment was repeated 3-5 times.
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RESULTS

COX-1 is required for p38 and JNK stress kinase activation
The MAP kinase family of proteins includes two subfamilies, the "classical" MAP kinases Erk1 and Erk2, which become activated in response to mitogenic stimuli, and the stressactivated kinases SAPK/JNK and p38, which are activated by oxidative or genotoxic stress, as well as by mitogens 23, 24 . Both MAP kinase subfamilies are activated following TCR engagement and participate in the activation of key transcription factors required for initiation of the genetic program of T cell activation 25 . We have previously shown that nonselective and COX-1 selective NSAID specifically inhibit TCR-dependent p38 activation in both transformed and normal T cells without affecting the activation of Erk 15 .
To address the potential role of COX-1 in the activation of JNK, the effect of NSAID on TCR-induced JNK activation was investigated. Although the costimulatory receptor CD28 can dramatically enhance JNK activation in T-cells 26 , engagement of the TCR in the absence of costimulation was sufficient to trigger the activation of the 46 kDa isoform of JNK (Fig.1A) , as determined by immunoblot analysis of Jurkat T-cell lysates with phosphospecific antibodies. Treatment of T cells with either the nonselective COX inhibitor ibuprofen or the COX-1 selective inhibitor sc-560 resulted in a strong inhibition of TCR-dependent JNK activation (Fig.1A) . As previously reported 15 , p38 activation was also inhibited (Fig.1B) , while Erk activation was unaffected (Fig.1C) . Consistent with the lack of COX-2 expression in unstimulated cells 14, 15 , no effect on either JNK or p38
For personal use only. by on April 14, 2008. www.bloodjournal.org From activation was observed in the presence of the COX-2 inhibitor NS-398 (Fig.1) . Similar results were obtained using freshly purified human peripheral blood lymphocytes (PBL) (Fig.1D) .
The block by NSAID of TCR-dependent JNK and p38 activation suggests that the products of COX -1 activity are required for TCR signaling. In support of this notion, treatment of Jurkat T cells with PGE2, one of the principal prostanoids produced by COX, resulted in recovery from the block in both JNK and p38 activation by sc-560 (Fig.2) . Furthermore, PGE2 enhanced JNK and p38 phosphorylation, but not Erk phosphorylation, following TCR engagement (Fig.1) . As previously shown for p38 15 , inhibition of JNK affects downstream events triggered by TCR engagement. Indeed, the JNK inhibitor, SP600125, blocked TCR dependent activation of the transcription factor NF-AT in a dose-dependent manner (supplemental figure 2) . Hence COX-1 generated prostanoids are required for activation of both members of the stress kinase subfamily of MAP kinases, but not of classical MAP kinases.
COX-1 controls an early step in the stress kinase cascade
The impairment in TCR-dependent activation of both JNK and p38 by nonselective and COX-1 selective NSAID suggests that COX-1, rather than directly modulating the activity of stress kinases, controls a component upstream of p38 and JNK in the TCR signaling cascade. Furthermore, since tyrosine kinase-dependent pathways leading to Erk and p38/JNK activation diverge at the level of the small GTPases Ras and Rac, respectively 27 The effect of COX-1 inhibition on Vav activation, as evaluated by its phosphorylation on tyrosine residues, was determined. A significant impairment in TCR-dependent Vav phosphorylation was observed in Jurkat cells (Fig.3A) , as well as in human PBL (data not shown) treated with the COX-1 inhibitor sc-560. A similar inhibition was observed in the presence of ibuprofen, while the COX-2 inhibitor NS-398 did not affect Vav phosphorylation (Fig.3A) . In agreement with the decrease in Vav phosphorylation, TCRdependent Rac activation was impaired in cells treated with sc-560 and ibuprofen, but not NS-398 (Fig.3B and data not shown) . Furthermore, TCR-dependent Pak1 phosphorylation, which occurs following its recruitment to GTP-bound Rac, was also reduced in sc-560 and ibuprofen-treated cells (Fig.3C and data not shown) . 32 . Vav is activated by phosphorylation on tyrosine residues, a process controlled by the tyrosine kinases Fyn and ZAP-70 33 .
COX-1 controls
Analysis of total lysates of cells treated with sc-560 showed an impairment in TCRdependent tyrosine phosphorylation of a subset of proteins (Fig.4A, see asterisks) , which suggests that a tyrosine kinase coupled to the TCR might be the target of COX-1.
We and others have previously shown that Lck, while essential for TCR signaling, is partially dispensable for Vav phosphorylation 32, 34 , suggesting that COX-1 might modulate a TCR-proximal pathway triggered by a tyrosine kinase other than Lck and selectively implicated in the activation of stress kinases through Vav. In support of this possibility, despite their capacity to inhibit Vav phosphorylation, no significant effect of sc-560 ( Fig.4B and data not shown for PBL) or ibuprofen (data not shown) was observed on the phosphorylation of CD3ζ, which crucially requires Lck 16, 35 . Accordingly, neither ZAP-70 phosphorylation (Fig.4C) , nor phosphorylation of its target, LAT (Fig.4D) On the other hand, Fyn plays a key role in Vav activation 33, 34 . This function is likely to be subserved by a pool of Fyn constitutively associated with CD3ζ 36,37 , which might be responsible for initiation of a Vav-dependent pathway regulating stress kinase activation independently of Lck and ZAP-70. The low levels of Fyn expressed in JCaM1 cells 35 figure 5A , a significant inhibition of TCRdependent Fyn activation was observed in the presence of sc-560 but not NS-398. Similar results were obtained on human PBL (Fig.5A) . Conversely, sc-560 did not affect TCRdependent activation of Lck (Fig.5B and data not shown for PBL). The notion that Fyn is selective target of COX-1 is further supported by the finding that activation of Pyk2, a FAK family protein tyrosine kinase associated to Fyn and activated by this kinase 38 , was impaired in cells treated with sc-560 and ibuprofen (Fig.5C ), but not NS-398 (data not shown). The possibility of an allosteric inhibition of Fyn by sc-560 was ruled out by in vitro kinase assays using purified Fyn (data not shown). In agreement with a role for COX in the control of Fyn, treatment with PGE2 resulted in enhanced Fyn activity (Fig.5D) . No effect of PGE2 was observed in vitro kinase assays using purified Fyn (data not shown), indicating that modulation of Fyn activity by PGE2 results from its interaction with a specific receptor.
To further address the functional connection between COX-1 and Fyn, we generated Jurkat T cell transfectants expressing constitutively active Fyn (F528Fyn) or Lck (F505Lck) mutants. Immunoblot analysis of total cell lysates showed that the levels of Fyn and Lck were increased by at least 2-fold in the respective transfectants, which was paralled by an increase in protein tyrosine phosphorylated proteins (Fig.6A) . As shown in figure 6 , sc-560 failed to inhibit JNK phosphorylation in cells expressing F528Fyn (Fig.6B ), but not in cells expressing F505Lck (Fig.6C) Although the immunosuppressive activity of NSAID on T cell activation might be mediated at least in part by PPAR, which block the activity of key transcription factors implicated in this process 13, 44 , this is not likely to interfere with early events in TCR signaling, which are triggered within minutes following TCR engagement. A COXindependent effect of NSAID on TCR signaling is also ruled out by the demonstration that PGE2, one of the principal products of COX activity, effectively reverses JNK and p38 inhibition by NSAID and enhances stress kinase activation. Paradoxically, exogenous PGE2 is a potent immunosuppressant, an activity related at least in part to its capacity to increase the levels of intracellular cyclic AMP and interfere with IL-2 gene transcription and cell cycle progression 10 . It can be hypothesized that excessive or inappropriate stimulation of the stress kinase pathway through Fyn/Vav/Pak1 might contribute to the immunosuppressive activity of PGE2 by interfering with early TCR signal transduction.
Although Fyn is essential for optimal T cell activation 45 , sustained elevation of Fyn activity, as well as selective association of CD3ζ with Fyn, are hallmarks of T cell anergy 46, 47 . Increasing the levels of Fyn expression in the Lck-deficient JCaM1 cells, while resulting in partial recovery of intracellular signaling in response to TCR engagement, is however accompanied by reduced IL-2 production and cell growth inhibition 35 . These effects correlate with anomalous CD3ζ phosphorylation and defective ZAP-70 activation, a phenotype reminiscent of altered peptide ligand-induced anergy 48, 49 . Furthermore, TCR engagement by antagonistic peptides results in increased Fyn activation and Vav phosphorylation, with little or no effect on Lck and ZAP-70 34 . Another potential target of COX-1 in early Fyn-dependent signaling is Csk, which negatively controls Src kinases. Csk has been shown to localize in lipid rafts, where it inhibits Lck activity, as the result of its interaction with tyrosine phosphorylated PAG, a transmembrane adaptor implicated in the negative regulation of T cell activation and a specific substrate of Fyn 50, 51 . Furthermore, enhancement of Csk activity by PGE2, resulting from PKA-mediated Csk phosphorylation, has been recently demonstrated 52 . shown to deliver a costimulatory signal in T cell activation 56 . Furthermore, phospholipase A2, which catalyzes the production of arachidonic acid, is essential for T cell activation and proliferation 57 . In this context, while the role of COX-2 in mitogenic signaling and carcinogenesis is well established, data obtained on COX-1 -/-mice suggest that also COX-1 might participate in this process 58 . It could be hypothesized that, as opposed to the effects evoked by treatment of T cells with exogenous PGE2, physiological levels of endogenous PGE2, produced in response to TCR engagement by preexisting COX-1 and subsequently sustained by newly expressed COX-2, might contribute, through its interaction with intracellular EP receptors 59 , both to the initiation of productive TCR signaling, and to subsequent signal extinction, and thereby participate in the orchestration of T cell activation. 
